Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta‐Analysis

ABSTRACT Background Type 2 diabetes mellitus (T2DM) often requires combination therapy when metformin alone becomes insufficient. Empagliflozin (SGLT2 inhibitor) and sitagliptin (DPP‐4 inhibitor) are commonly used add‐on agents with differing metabolic profiles. This systematic review and meta‐analy...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Saad Ashraf, Muhammad Burhan, Sara Sarwar, Ahila Ali, Aiza Ahsan, Shahzad Ashraf, Hammad Javaid, Hamza Irfan, Muhammad Hamza Naseer Awan, Ajeet Singh, Biruk Demisse Ayalew
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2026-05-01
Colecção:	Endocrinology, Diabetes & Metabolism
Assuntos:	cardiometabolic outcomes empagliflozin meta‐analysis metformin sitagliptin type 2 diabetes
Acesso em linha:	https://doi.org/10.1002/edm2.70238
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!